AP2287A - Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication. - Google Patents
Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication.Info
- Publication number
- AP2287A AP2287A AP2006003579A AP2006003579A AP2287A AP 2287 A AP2287 A AP 2287A AP 2006003579 A AP2006003579 A AP 2006003579A AP 2006003579 A AP2006003579 A AP 2006003579A AP 2287 A AP2287 A AP 2287A
- Authority
- AP
- ARIPO
- Prior art keywords
- acylsulfonamides
- inhibitors
- carboxylic acids
- hcv replication
- macrocyclic carboxylic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US51154103P | 2003-10-14 | 2003-10-14 | |
US61246004P | 2004-09-22 | 2004-09-22 | |
PCT/US2004/033970 WO2005037214A2 (fr) | 2003-10-14 | 2004-10-13 | Acylsulfonamides et acides carboxyliques macrocycliques utilises en tant qu'inhibiteurs de la replication du virus de l'hepatite c |
Publications (2)
Publication Number | Publication Date |
---|---|
AP2006003579A0 AP2006003579A0 (en) | 2006-04-30 |
AP2287A true AP2287A (en) | 2011-10-31 |
Family
ID=34467992
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AP2006003579A AP2287A (en) | 2003-10-14 | 2004-10-13 | Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication. |
AP2011005830A AP2011005830A0 (en) | 2003-10-14 | 2006-04-11 | Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AP2011005830A AP2011005830A0 (en) | 2003-10-14 | 2006-04-11 | Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication. |
Country Status (30)
Country | Link |
---|---|
EP (2) | EP2407470A3 (fr) |
JP (3) | JP4584260B2 (fr) |
KR (1) | KR100853579B1 (fr) |
CN (2) | CN102020697B (fr) |
AP (2) | AP2287A (fr) |
AR (2) | AR046422A1 (fr) |
AU (1) | AU2004281780B2 (fr) |
BR (1) | BRPI0415373A (fr) |
CA (1) | CA2540858C (fr) |
CY (1) | CY1113809T1 (fr) |
DK (1) | DK1680137T3 (fr) |
EA (1) | EA011857B8 (fr) |
EC (2) | ECSP066570A (fr) |
ES (1) | ES2398912T3 (fr) |
GE (1) | GEP20084560B (fr) |
HK (2) | HK1100164A1 (fr) |
HR (1) | HRP20130098T1 (fr) |
IL (3) | IL174704A (fr) |
IS (1) | IS2876B (fr) |
MA (1) | MA28152A1 (fr) |
MX (1) | MXPA06003963A (fr) |
MY (1) | MY144593A (fr) |
NO (1) | NO343231B1 (fr) |
NZ (1) | NZ546347A (fr) |
OA (1) | OA13315A (fr) |
PL (1) | PL1680137T3 (fr) |
PT (1) | PT1680137E (fr) |
RS (3) | RS20110578A3 (fr) |
TW (2) | TWI375679B (fr) |
WO (1) | WO2005037214A2 (fr) |
Families Citing this family (141)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
US7176208B2 (en) | 2003-04-18 | 2007-02-13 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors |
EP2407470A3 (fr) * | 2003-10-14 | 2015-06-10 | F. Hoffmann-La Roche Ltd. | Acylsulfonamides et acides carboxyliques macrocycliques utilisés en tant qu'inhibiteurs de la réplication du virus de l'hépatite C |
US20050182252A1 (en) | 2004-02-13 | 2005-08-18 | Reddy K. R. | Novel 2'-C-methyl nucleoside derivatives |
EA012389B1 (ru) * | 2004-03-30 | 2009-10-30 | Интермун, Инк. | Макроциклические соединения в качестве ингибиторов вирусной репликации |
US7323447B2 (en) | 2005-02-08 | 2008-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
EP2332963A3 (fr) * | 2005-03-08 | 2011-11-16 | Boehringer Ingelheim International Gmbh | Procédé pour la préparation de composés macrocycliques |
WO2006109085A1 (fr) * | 2005-04-13 | 2006-10-19 | Astex Therapeutics Limited | Derives d'hydroxybenzamide et leur utilisation comme inhibteurs de hsp90 |
US7592336B2 (en) | 2005-05-10 | 2009-09-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2007002051A1 (fr) * | 2005-06-22 | 2007-01-04 | Smithkline Beecham Corporation | Derives de carboline et leur utilisation en tant qu'inhibiteurs d'infections a flaviridae |
US7601686B2 (en) * | 2005-07-11 | 2009-10-13 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
BRPI0613962A2 (pt) | 2005-07-25 | 2009-03-24 | Intermune Inc | inibidores macrocìclicos inovadores de replicação de vìrus da hepatite c |
AR055105A1 (es) | 2005-07-29 | 2007-08-08 | Tibotec Pharm Ltd | Inhibidores macrociclicos del virus de la hepatitis c |
AU2006274862B2 (en) * | 2005-07-29 | 2012-03-22 | Medivir Ab | Macrocyclic inhibitors of hepatitis C virus |
US7666834B2 (en) | 2005-07-29 | 2010-02-23 | Tibotec Pharmaceuticals Ltd. | Macrocyclic inhibitors of hepatitis C virus |
EP1915378A4 (fr) | 2005-08-12 | 2009-07-22 | Boehringer Ingelheim Int | Inhibiteurs de polymerase virale |
AR055395A1 (es) | 2005-08-26 | 2007-08-22 | Vertex Pharma | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c |
GEP20104956B (en) * | 2005-10-11 | 2010-04-12 | Array Biopharma Inc | Compounds for inhibiting hepatitis c viral replication and use thereof |
US7772183B2 (en) | 2005-10-12 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7741281B2 (en) | 2005-11-03 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
DK1966130T3 (da) | 2005-12-23 | 2014-02-10 | Zealand Pharma As | Modificerede lysin-mimetiske forbindelser |
US7816348B2 (en) | 2006-02-03 | 2010-10-19 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
US7935670B2 (en) | 2006-07-11 | 2011-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7906619B2 (en) | 2006-07-13 | 2011-03-15 | Achillion Pharmaceuticals, Inc. | 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication |
RU2009109355A (ru) | 2006-08-17 | 2010-09-27 | БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) | Ингибиторы вырусной полимеразы |
US8604244B2 (en) | 2010-07-02 | 2013-12-10 | Reviva Pharmaceuticals, Inc. | Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives |
EP2066329B1 (fr) | 2006-09-15 | 2017-09-06 | Reviva Pharmaceuticals, Inc. | Synthèse, utilisation et compositions de cyclobutylméthylamines |
WO2008044054A2 (fr) | 2006-10-12 | 2008-04-17 | Astex Therapeutics Limited | Composés pharmaceutiques |
WO2008044045A1 (fr) | 2006-10-12 | 2008-04-17 | Astex Therapeutics Limited | Combinaisons pharmaceutiques |
JP5528806B2 (ja) | 2006-10-12 | 2014-06-25 | アステックス、セラピューティックス、リミテッド | 複合薬剤 |
GB0620259D0 (en) | 2006-10-12 | 2006-11-22 | Astex Therapeutics Ltd | Pharmaceutical compounds |
US8343477B2 (en) | 2006-11-01 | 2013-01-01 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
US7772180B2 (en) | 2006-11-09 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8003604B2 (en) | 2006-11-16 | 2011-08-23 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7763584B2 (en) | 2006-11-16 | 2010-07-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7888464B2 (en) | 2006-11-16 | 2011-02-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2008079266A2 (fr) | 2006-12-21 | 2008-07-03 | Wyeth | Synthèse de composés de pyrrolidine |
CN101668538A (zh) * | 2007-01-08 | 2010-03-10 | 芬诺密克斯公司 | 大环类丙型肝炎蛋白酶抑制剂 |
MX2009008275A (es) * | 2007-02-01 | 2009-08-12 | Tibotec Pharm Ltd | Formas polimorficas de un inhibidor macrociclico del virus de la hepatitis c. |
WO2008106130A2 (fr) | 2007-02-26 | 2008-09-04 | Achillion Pharmaceuticals, Inc. | Peptides substitués par une amine tertiaire utiles comme inhibiteurs de la réplication du virus de l'hépatite c |
US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
AU2008240834B2 (en) * | 2007-04-24 | 2012-08-23 | F. Hoffmann-La Roche Ag | Process for HCV protease inhibitor intermediate |
NZ581606A (en) * | 2007-05-03 | 2012-06-29 | Intermune Inc | Novel macrocyclic inhibitors of hepatitis c virus replication |
AU2008251425A1 (en) | 2007-05-10 | 2008-11-20 | Array Biopharma, Inc. | Novel peptide inhibitors of hepatitis C virus replication |
AP2874A (en) * | 2007-06-29 | 2014-03-31 | Gilead Sciences Inc | Antiviral compounds |
TW200914013A (en) | 2007-06-29 | 2009-04-01 | Gilead Sciences Inc | Antiviral compounds |
SE531698C2 (sv) | 2007-07-12 | 2009-07-07 | Respiratorius Ab | Nya bronkdilaterande a,b-omättade amider |
US8242140B2 (en) | 2007-08-03 | 2012-08-14 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
MX2007009796A (es) | 2007-08-14 | 2009-02-25 | Cell Therapy And Technology S | Gel conteniendo pirfenidona. |
CA2708150A1 (fr) | 2007-12-05 | 2009-06-18 | Enanta Pharmaceuticals, Inc. | Composes a base de tripeptides fluores inhibant la serine protease du vhc |
JP5623289B2 (ja) | 2007-12-19 | 2014-11-12 | ベーリンガーインゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ウイルスポリメラーゼインヒビター |
TW201546079A (zh) | 2007-12-21 | 2015-12-16 | Celgene Avilomics Res Inc | Hcv蛋白酶抑制劑及其用途(一) |
KR101629523B1 (ko) * | 2007-12-21 | 2016-06-10 | 에프. 호프만-라 로슈 아게 | 대환 화합물의 제조방법 |
US8293705B2 (en) | 2007-12-21 | 2012-10-23 | Avila Therapeutics, Inc. | HCV protease inhibitors and uses thereof |
CN101951770B (zh) | 2007-12-21 | 2014-12-31 | 阿维拉制药公司 | Hcv蛋白酶抑制剂和其用途 |
US8202996B2 (en) | 2007-12-21 | 2012-06-19 | Bristol-Myers Squibb Company | Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide |
US8309685B2 (en) | 2007-12-21 | 2012-11-13 | Celgene Avilomics Research, Inc. | HCV protease inhibitors and uses thereof |
MX2010008523A (es) | 2008-02-04 | 2010-08-31 | Idenix Pharmaceuticals Inc | Inhibidores macrociclicos de serina proteasa. |
BRPI0909205A2 (pt) | 2008-04-11 | 2015-08-11 | Hoffmann La Roche | Complexos de rutênio como catalizadores para reações de metátese |
AP2010005416A0 (en) * | 2008-04-15 | 2010-10-31 | Intermune Inc | Novel macrocyclic inhibitors of hepatitis c virus replication. |
US8163921B2 (en) | 2008-04-16 | 2012-04-24 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
CA2722867A1 (fr) | 2008-05-09 | 2009-11-12 | Boehringer Ingelheim International Gmbh | Procede pour la fabrication de macrocycles |
EP2300491B1 (fr) | 2008-05-29 | 2016-01-06 | Bristol-Myers Squibb Company | Inhibiteurs du virus de l hépatite c |
US7964560B2 (en) | 2008-05-29 | 2011-06-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
KR101647520B1 (ko) * | 2008-08-07 | 2016-08-10 | 에프. 호프만-라 로슈 아게 | 거대환식 화합물의 제조 방법 |
AU2009290137A1 (en) * | 2008-09-03 | 2010-03-11 | Xenome Ltd | Libraries of peptide conjugates and methods for making them |
US8207341B2 (en) | 2008-09-04 | 2012-06-26 | Bristol-Myers Squibb Company | Process or synthesizing substituted isoquinolines |
UY32099A (es) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
US8044087B2 (en) | 2008-09-29 | 2011-10-25 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8563505B2 (en) | 2008-09-29 | 2013-10-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2010068760A2 (fr) | 2008-12-10 | 2010-06-17 | Achillion Pharmaceuticals, Inc. | Nouveaux peptides 4-amino-4-oxobutanoyl utiles en tant qu'inhibiteurs de la réplication virale |
US8283310B2 (en) | 2008-12-15 | 2012-10-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
EA201100851A1 (ru) | 2008-12-23 | 2012-04-30 | Фармассет, Инк. | Аналоги нуклеозидов |
NZ593648A (en) | 2008-12-23 | 2013-09-27 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
CL2009002206A1 (es) | 2008-12-23 | 2011-08-26 | Gilead Pharmasset Llc | Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales. |
AU2010203656A1 (en) | 2009-01-07 | 2011-07-21 | Scynexis, Inc. | Cyclosporine derivative for use in the treatment of HCV and HIV infection |
GB0900914D0 (en) | 2009-01-20 | 2009-03-04 | Angeletti P Ist Richerche Bio | Antiviral agents |
AR075584A1 (es) * | 2009-02-27 | 2011-04-20 | Intermune Inc | COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO. |
JP5690286B2 (ja) | 2009-03-04 | 2015-03-25 | イデニク プハルマセウティカルス,インコーポレイテッド | ホスホチオフェン及びホスホチアゾールhcvポリメラーゼ阻害剤 |
WO2010118078A1 (fr) | 2009-04-08 | 2010-10-14 | Idenix Pharmaceuticals, Inc. | Inhibiteurs macrocycliques de la sérine protéase |
CA2761650C (fr) | 2009-05-13 | 2015-05-26 | Enanta Pharmaceuticals, Inc. | Composes macrocycliques comme inhibiteurs du virus de l'hepatite c |
US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
TWI576352B (zh) | 2009-05-20 | 2017-04-01 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
EP2445340B1 (fr) | 2009-06-22 | 2016-05-18 | Millennium Pharmaceuticals, Inc. | Acides hydroxamiques substitués et leurs utilisations |
US8232246B2 (en) | 2009-06-30 | 2012-07-31 | Abbott Laboratories | Anti-viral compounds |
WO2011017389A1 (fr) | 2009-08-05 | 2011-02-10 | Idenix Pharmaceuticals, Inc. | Inhibiteurs macrocycliques de la sérine protéase macrocyclique utiles contre les infections virales, en particulier le virus de lhépatite c |
CN102741270B (zh) * | 2009-09-28 | 2015-07-22 | 英特穆恩公司 | C型肝炎病毒复制的环肽抑制剂 |
US20110129444A1 (en) * | 2009-09-28 | 2011-06-02 | Intermune, Inc | Novel macrocyclic inhibitors of hepatitis c virus replication |
JP2013508350A (ja) | 2009-10-20 | 2013-03-07 | ファイザー・インク | ガンマ−セクレターゼモジュレーターとしての新規なヘテロアリールイミダゾールおよびヘテロアリールトリアゾール |
WO2011063076A1 (fr) | 2009-11-19 | 2011-05-26 | Itherx Pharmaceuticals, Inc. | Méthodes de traitement du virus de l'hépatite c avec des composés d'oxo-acétamide |
MY159958A (en) | 2009-12-18 | 2017-02-15 | Idenix Pharmaceuticals Inc | 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors |
US8933110B2 (en) | 2010-01-25 | 2015-01-13 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
US8785487B2 (en) | 2010-01-25 | 2014-07-22 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
US8653025B2 (en) * | 2010-01-27 | 2014-02-18 | AB Pharma Ltd. | Polyheterocyclic compounds highly potent as HCV inhibitors |
EP2609923B1 (fr) | 2010-03-31 | 2017-05-24 | Gilead Pharmasset LLC | Procede de crystallisation de (s)-isopropyl 2-(((s)-(perfluorophenoxy)(phenoxy)phosphoryl)amino)propanoate |
BR112012024884A2 (pt) | 2010-03-31 | 2016-10-18 | Gilead Pharmasset Llc | síntese estereosseletiva de ativos contendo fósforo |
KR101990279B1 (ko) | 2010-09-21 | 2019-06-19 | 이난타 파마슈티칼스, 인코포레이티드 | 매크로사이클릭 프롤린 유도된 hcv 세린 프로테아제 억제제 |
EP2455068A1 (fr) * | 2010-11-09 | 2012-05-23 | F. Hoffmann-La Roche AG | Composition pharmaceutique pour le traitement d'infections par VHC |
WO2012062691A1 (fr) | 2010-11-09 | 2012-05-18 | F. Hoffmann-La Roche Ag | Compositions pharmaceutiques pour le traitement des infections par le virus de l'hépatite c |
TW201238950A (en) * | 2010-11-15 | 2012-10-01 | Abbott Lab | NAMPT and rock inhibitors |
MY180279A (en) | 2010-11-18 | 2020-11-26 | Metalysis Ltd | Electrolysis apparatus |
AR084044A1 (es) | 2010-11-30 | 2013-04-17 | Pharmasset Inc | Compuestos 2’-espiro-nucleosidos |
MX2013007698A (es) | 2010-12-30 | 2013-08-15 | Abbvie Inc | Inhibidores de serina proteasa de hepatitis c macrociclicos de fenantridina. |
EP2658859A4 (fr) | 2010-12-30 | 2014-07-30 | Enanta Pharm Inc | Inhibiteurs macrocycliques de sérine protéase d'hépatite c |
CN103443092B (zh) | 2011-02-03 | 2015-11-25 | 鲁平有限公司 | 用作α7胆碱受体调节剂的吡咯衍生物 |
US9353100B2 (en) | 2011-02-10 | 2016-05-31 | Idenix Pharmaceuticals Llc | Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections |
US20120252721A1 (en) | 2011-03-31 | 2012-10-04 | Idenix Pharmaceuticals, Inc. | Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor |
US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
US8691757B2 (en) | 2011-06-15 | 2014-04-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
AU2012269643A1 (en) | 2011-06-16 | 2014-02-06 | AB Pharma Ltd. | Macrocyclic heterocyclic compound for inhibiting hepatitis C virus and preparation and use thereof |
AR088383A1 (es) | 2011-10-18 | 2014-05-28 | Coherus Biosciences Inc | Formulaciones de etanercept estabilizadas con combinaciones de azucares y polioles |
US10493151B2 (en) | 2011-10-18 | 2019-12-03 | Coherus Biosciences, Inc. | Etanercept formulations stabilized with sodium chloride |
US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
DK2583680T1 (da) | 2011-10-21 | 2015-01-19 | Abbvie Inc | Mono (PSI-7977) eller kombinationsbehandling af DAA til anvendelse ved behandling af HCV |
CN104383541A (zh) | 2011-10-21 | 2015-03-04 | 艾伯维公司 | 用于治疗hcv的包含至少两种直接抗病毒剂和利巴韦林但无干扰素的方法 |
US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
SG11201403165SA (en) | 2011-12-30 | 2014-08-28 | Reviva Pharmaceuticals Inc | Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives |
MX346763B (es) | 2012-03-28 | 2017-03-31 | Cell Therapy And Tech S A De C V | Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné. |
EP2869816A4 (fr) * | 2012-07-09 | 2016-04-20 | Coherus Biosciences Inc | Formulations d'étanercept présentant une réduction marquée en particules invisibles à l' il nu |
AU2013315750B9 (en) | 2012-09-11 | 2018-11-15 | Coherus Biosciences, Inc. | Correctly folded etanercept in high purity and excellent yield |
RS55592B1 (sr) | 2012-10-19 | 2017-06-30 | Bristol Myers Squibb Co | 9-metil supstituisani heksadekahidrociklopropa(e)pirolo(1,2-a)(1,4)diazaciklopentadecinil karbamat derivati kao nestrukturalni 3 (ns3) proteazni inhibitori za lečenje infekcijavirusom hepatitisa c |
US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2014070964A1 (fr) | 2012-11-02 | 2014-05-08 | Bristol-Myers Squibb Company | Inhibiteurs du virus de l'hépatite c |
WO2014071007A1 (fr) | 2012-11-02 | 2014-05-08 | Bristol-Myers Squibb Company | Inhibiteurs du virus de l'hépatite c |
EP2914614B1 (fr) | 2012-11-05 | 2017-08-16 | Bristol-Myers Squibb Company | Inhibiteurs du virus de l'hépatite c |
WO2014137869A1 (fr) | 2013-03-07 | 2014-09-12 | Bristol-Myers Squibb Company | Inhibiteurs du virus de l'hépatite c |
EP2970195B1 (fr) | 2013-03-14 | 2017-08-02 | Achillion Pharmaceuticals, Inc. | Processus de production de sovaprevir |
US9085607B2 (en) | 2013-03-15 | 2015-07-21 | Achillion Pharmaceuticals, Inc. | ACH-0142684 sodium salt polymorph, composition including the same, and method of manufacture thereof |
MX2015013020A (es) | 2013-03-15 | 2016-06-10 | Achillion Pharmaceuticals Inc | Polimorfos de sovaprevir y metodos de fabricacion de los mismos. |
US9006423B2 (en) | 2013-03-15 | 2015-04-14 | Achillion Pharmaceuticals Inc. | Process for making a 4-amino-4-oxobutanoyl peptide cyclic analogue, an inhibitor of viral replication, and intermediates thereof |
ES2792503T3 (es) | 2013-08-27 | 2020-11-11 | Gilead Pharmasset Llc | Formulación combinada de dos compuestos antivirales |
EP3046924A1 (fr) | 2013-09-20 | 2016-07-27 | IDENIX Pharmaceuticals, Inc. | Inhibiteurs du virus de l'hépatite c |
WO2015103490A1 (fr) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Formes galéniques antivirales solides |
US20170066779A1 (en) | 2014-03-05 | 2017-03-09 | Idenix Pharmaceuticals Llc | Solid forms of a flaviviridae virus inhibitor compound and salts thereof |
US20170135990A1 (en) | 2014-03-05 | 2017-05-18 | Idenix Pharmaceuticals Llc | Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection |
CN105175491B (zh) * | 2015-07-13 | 2019-01-11 | 山东大学 | 一种含有羟脯氨酸骨架的多肽类ns3丝氨酸蛋白酶抑制剂及其制备方法和应用 |
CA3022119A1 (fr) | 2016-04-28 | 2017-11-02 | Emory University | Compositions therapeutiques a base de nucleotides et nucleosides contenant un alcyne et utilisations associees |
JP6989864B2 (ja) | 2017-05-05 | 2022-02-03 | ジーランド ファーマ,アー/エス | ギャップ結合細胞間コミュニケーションモジュレータ及び糖尿病性眼疾患の治療のためのそれらの使用 |
US20230218644A1 (en) | 2020-04-16 | 2023-07-13 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003053349A2 (fr) * | 2001-12-20 | 2003-07-03 | Bristol-Myers Squibb Company | Inhibiteurs de virus de l'hepatite c |
WO2003066103A1 (fr) * | 2002-02-07 | 2003-08-14 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compositions pharmaceutiques pour inhibiteurs de protease virale de l'hepatite c |
US6608027B1 (en) * | 1999-04-06 | 2003-08-19 | Boehringer Ingelheim (Canada) Ltd | Macrocyclic peptides active against the hepatitis C virus |
Family Cites Families (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3547119A (en) | 1967-12-08 | 1970-12-15 | Baxter Laboratories Inc | Catheter assembly |
US4211771A (en) | 1971-06-01 | 1980-07-08 | Robins Ronald K | Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide |
US4052509A (en) | 1972-12-18 | 1977-10-04 | Affiliated Medical Research, Inc. | Method for reducing serum uric acid levels |
US3839346A (en) | 1972-12-18 | 1974-10-01 | Affiliated Med Res | N-substituted pyridone and general method for preparing pyridones |
CA1049411A (fr) | 1972-12-18 | 1979-02-27 | Affiliated Medical Research | Pyridone n-substituee; methode generale de synthese des pyridones |
US4042699A (en) | 1972-12-18 | 1977-08-16 | Affiliated Medical Research, Inc. | Method for reducing serum glucose levels |
US4311137A (en) | 1980-04-30 | 1982-01-19 | Sherwood Medical Industries Inc. | Infusion device |
US6936694B1 (en) | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
US4531937A (en) | 1983-01-24 | 1985-07-30 | Pacesetter Systems, Inc. | Introducer catheter apparatus and method of use |
MX9203641A (es) | 1983-12-16 | 1992-07-01 | Genentech Inc | Interferones gamma recombinantes que poseen estabilidad mejorada y metodos biotecnologicos para su obtencion. |
US4855238A (en) | 1983-12-16 | 1989-08-08 | Genentech, Inc. | Recombinant gamma interferons having enhanced stability and methods therefor |
US4806347A (en) | 1985-12-11 | 1989-02-21 | Schering Corporation | Interferon combinations |
US4755173A (en) | 1986-02-25 | 1988-07-05 | Pacesetter Infusion, Ltd. | Soft cannula subcutaneous injection set |
US5082659A (en) | 1986-10-06 | 1992-01-21 | Board Of Regents, The University Of Texas System | Methods and compositions employing interferon-gamma |
ES2039276T3 (es) | 1987-01-20 | 1993-09-16 | Schering Corporation | Uso de una combinacion de interferon gamma e interferon alfa para la preparacion de un medicamento para el tratamiento de ciertas leucemias. |
US5190751A (en) | 1987-01-20 | 1993-03-02 | Schering Corporation | Treatment of certain leukemias with a combination of gamma interferon and alpha interferon |
WO1988009673A1 (fr) | 1987-06-02 | 1988-12-15 | Schering Corporation | Traitement de l'hepatite b de type chronique avec une combinaison d'interferons alpha et gamma humains recombinants |
ES2012739T5 (es) * | 1987-11-18 | 2001-12-01 | Chiron Corp | Diagnosticos para nanbv. |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
GB8904009D0 (en) | 1989-02-22 | 1989-04-05 | Celltech Ltd | Vector |
US5605690A (en) | 1989-09-05 | 1997-02-25 | Immunex Corporation | Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor |
US5395760A (en) | 1989-09-05 | 1995-03-07 | Immunex Corporation | DNA encoding tumor necrosis factor-α and -β receptors |
US5716632A (en) | 1989-11-22 | 1998-02-10 | Margolin; Solomon B. | Compositions and methods for reparation and prevention of fibrotic lesions |
US5518729A (en) | 1989-11-22 | 1996-05-21 | Margolin; Solomon B. | Compositions and methods for reparation and prevention of fibrotic lesions |
US5310562A (en) | 1989-11-22 | 1994-05-10 | Margolin Solomon B | Composition and method for reparation and prevention of fibrotic lesions |
US5165424A (en) | 1990-08-09 | 1992-11-24 | Silverman Harvey N | Method and system for whitening teeth |
US5372808A (en) | 1990-10-17 | 1994-12-13 | Amgen Inc. | Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect |
US5574132A (en) * | 1991-04-05 | 1996-11-12 | Biochem Immunosystems Inc. | Peptides and mixtures thereof for detecting antibodies to hepatitis C virus (HCV) |
DK0787807T3 (da) * | 1991-08-27 | 2003-08-11 | Hoffmann La Roche | Primere og prober til detektion af hepatitis C |
US5610054A (en) | 1992-05-14 | 1997-03-11 | Ribozyme Pharmaceuticals, Inc. | Enzymatic RNA molecule targeted against Hepatitis C virus |
US5382657A (en) | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
US5545143A (en) | 1993-01-21 | 1996-08-13 | T. S. I. Medical | Device for subcutaneous medication delivery |
US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
DK0730470T3 (da) | 1993-11-10 | 2002-06-03 | Enzon Inc | Forbedrede interferonpolymerkonjugater |
US5951974A (en) | 1993-11-10 | 1999-09-14 | Enzon, Inc. | Interferon polymer conjugates |
US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
US5559101A (en) | 1994-10-24 | 1996-09-24 | Genencor International, Inc. | L-ribofuranosyl nucleosides |
IL116730A0 (en) | 1995-01-13 | 1996-05-14 | Amgen Inc | Chemically modified interferon |
US6090822A (en) | 1995-03-03 | 2000-07-18 | Margolin; Solomon B. | Treatment of cytokine growth factor caused disorders |
US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
GB9517022D0 (en) | 1995-08-19 | 1995-10-25 | Glaxo Group Ltd | Medicaments |
US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
US5980884A (en) | 1996-02-05 | 1999-11-09 | Amgen, Inc. | Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon |
US5908121A (en) | 1996-03-11 | 1999-06-01 | Dardashti; Shahriar | Adjustable display assembly |
US5633388A (en) | 1996-03-29 | 1997-05-27 | Viropharma Incorporated | Compounds, compositions and methods for treatment of hepatitis C |
EP0907659A1 (fr) | 1996-05-10 | 1999-04-14 | Schering Corporation | Inhibiteurs synthetiques de la protease ns3 du virus de l'hepatite c |
CZ123099A3 (cs) | 1996-10-09 | 1999-11-17 | Boehringer Mannheim Pharmaceuticals Corporation - Smithkline Beecham Corporation Limited Partnership No. 1 | Farmaceutický prostředek pro inhibici stresem-aktivovaných protein kinas |
ATE271063T1 (de) | 1996-10-16 | 2004-07-15 | Icn Pharmaceuticals | Purin-l-nukleoside, deren analoga und verwendungen |
IL129407A0 (en) | 1996-10-18 | 2000-02-17 | Vertex Pharma | Inhibitors of serine proteases particularly hepatitis C virus NS3 protease pharmaceutical compositions containing the same and the use thereof |
GB9623908D0 (en) | 1996-11-18 | 1997-01-08 | Hoffmann La Roche | Amino acid derivatives |
AU7127298A (en) | 1997-04-14 | 1998-11-11 | Emory University | Serine protease inhibitors |
GB9707659D0 (en) | 1997-04-16 | 1997-06-04 | Peptide Therapeutics Ltd | Hepatitis C NS3 Protease inhibitors |
TW517055B (en) | 1997-07-02 | 2003-01-11 | Smithkline Beecham Corp | Novel substituted imidazole compounds |
US6489325B1 (en) | 1998-07-01 | 2002-12-03 | Smithkline Beecham Corporation | Substituted imidazole compounds |
NZ503263A (en) | 1997-08-11 | 2002-10-25 | Boehringer Ingelheim Ca Ltd | Hepatitis C NS3 protease inhibitor peptides and peptide analogues |
ES2241157T3 (es) | 1997-08-11 | 2005-10-16 | Boehringer Ingelheim (Canada) Ltd. | Peptidos inhibidores de la hepatitis c. |
US6172046B1 (en) | 1997-09-21 | 2001-01-09 | Schering Corporation | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
JP2001525470A (ja) | 1997-12-12 | 2001-12-11 | マクロメド・インコーポレーテッド | タンパク修飾のためのヘテロ官能化星形ポリ(エチレングリコール) |
US5981709A (en) | 1997-12-19 | 1999-11-09 | Enzon, Inc. | α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same |
US5985263A (en) | 1997-12-19 | 1999-11-16 | Enzon, Inc. | Substantially pure histidine-linked protein polymer conjugates |
US6423695B1 (en) | 1998-01-13 | 2002-07-23 | Ribapharm, Inc. | Cytokine related treatments of disease |
IT1299134B1 (it) | 1998-02-02 | 2000-02-29 | Angeletti P Ist Richerche Bio | Procedimento per la produzione di peptidi con proprieta' inibitrici della proteasi ns3 del virus hcv, peptidi cosi' ottenibili e peptidi |
AU3376699A (en) | 1998-03-31 | 1999-10-18 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
CN1548436A (zh) | 1998-05-22 | 2004-11-24 | ʷ��˿�������ȳ�ķ����˾ | 新的2-烷基取代咪唑化合物 |
GB9812523D0 (en) | 1998-06-10 | 1998-08-05 | Angeletti P Ist Richerche Bio | Peptide inhibitors of hepatitis c virus ns3 protease |
AU756627B2 (en) | 1998-07-27 | 2003-01-16 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Diketoacid-derivatives as inhibitors of polymerases |
US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
AR022061A1 (es) | 1998-08-10 | 2002-09-04 | Boehringer Ingelheim Ca Ltd | Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos. |
US6440985B1 (en) | 1998-09-04 | 2002-08-27 | Viropharma Incorporated | Methods for treating viral infections |
US6277830B1 (en) | 1998-10-16 | 2001-08-21 | Schering Corporation | 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon |
US6288089B1 (en) | 1998-12-21 | 2001-09-11 | Michael Zawada | Use of kinase inhibitors for treating neurodegenerative diseases |
US6245740B1 (en) | 1998-12-23 | 2001-06-12 | Amgen Inc. | Polyol:oil suspensions for the sustained release of proteins |
UA74546C2 (en) | 1999-04-06 | 2006-01-16 | Boehringer Ingelheim Ca Ltd | Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition |
MXPA01011045A (es) | 1999-05-04 | 2002-07-22 | Boehringer Ingelheim Ltd | Sistema sustituto basado en celulas y metodo para evaluar la actividad de la proteasa ns3 de virus de la hepatitis c. |
SK8292002A3 (en) | 1999-11-12 | 2002-12-03 | Maxygen Holdings Ltd | A conjugate exhibiting interferon gamma activity, nucleotide sequence encoding for a polypeptide fraction of conjugate, an expression vector and a host cell containing nucleotide sequence, pharmaceutical composition comprising the same and use thereof |
AU763356C (en) | 1999-12-27 | 2004-08-26 | Japan Tobacco Inc. | Fused-ring compounds and use thereof as drugs |
US6943161B2 (en) | 1999-12-28 | 2005-09-13 | Pharmacopela Drug Discovery, Inc. | Pyrimidine and triazine kinase inhibitors |
EP1292310A1 (fr) | 2000-05-10 | 2003-03-19 | SmithKline Beecham Corporation | Nouveaux anti-infectieux |
AU2001260081B2 (en) | 2000-05-22 | 2005-07-28 | Leo Pharma A/S | Benzophenones as inhibitors of il-1beta and tnf-alpha |
MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
US6448281B1 (en) | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
GB0017676D0 (en) | 2000-07-19 | 2000-09-06 | Angeletti P Ist Richerche Bio | Inhibitors of viral polymerase |
MXPA03006514A (es) | 2001-01-22 | 2004-12-02 | Merck & Co Inc | Derivados de nucleosidos como inhibidores de polimerasa de acido ribonucleico viral dependiente de acido ribonucleico. |
WO2002064456A1 (fr) * | 2001-02-12 | 2002-08-22 | Flextank Pty Ltd | Vessies de stockage pour du vin ou des aliments liquides destinees a etre enfermees dans un contenant |
WO2002069903A2 (fr) | 2001-03-06 | 2002-09-12 | Biocryst Pharmaceuticals, Inc. | Nucleosides, leur preparation et utilisation en tant qu'inhibiteurs de polymerases virales d'arn |
WO2002083622A2 (fr) | 2001-04-10 | 2002-10-24 | Leo Pharma A/S | Nouveaux derives d'aminophenyle cetone |
EP1256628A3 (fr) | 2001-05-10 | 2003-03-19 | Agouron Pharmaceuticals, Inc. | ARN polymerase NS5B du virus de la hepatite C et mutants derivés de la polymerase |
AR036081A1 (es) | 2001-06-07 | 2004-08-11 | Smithkline Beecham Corp | Compuesto de 1,2-dihidroquinolina, su uso para preparar una composicion farmaceutica, metodos para prepararlo y compuestos del acido 2-aminobenzoico n-alquilado de utilidad como intermediarios en dichos metodos |
ATE438637T1 (de) | 2001-06-11 | 2009-08-15 | Virochem Pharma Inc | Thiophenderivate als antivirale mittel gegen flavivirus-infektion |
CA2449999C (fr) | 2001-06-11 | 2012-07-31 | Shire Biochem Inc. | Composes et methodes de traitement ou de prevention d'infections a flavirus |
AR035543A1 (es) | 2001-06-26 | 2004-06-16 | Japan Tobacco Inc | Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con |
CA2369711A1 (fr) * | 2002-01-30 | 2003-07-30 | Boehringer Ingelheim (Canada) Ltd. | Peptides macrocycliques qui agissent contre le virus de l'hepatite c |
CA2370396A1 (fr) * | 2002-02-01 | 2003-08-01 | Boehringer Ingelheim (Canada) Ltd. | Tri-peptides inhibiteur de l'hepatite c |
CA2369970A1 (fr) | 2002-02-01 | 2003-08-01 | Boehringer Ingelheim (Canada) Ltd. | Tri-peptides inhibiteur de l'hepatite c |
EP2407470A3 (fr) * | 2003-10-14 | 2015-06-10 | F. Hoffmann-La Roche Ltd. | Acylsulfonamides et acides carboxyliques macrocycliques utilisés en tant qu'inhibiteurs de la réplication du virus de l'hépatite C |
-
2004
- 2004-10-13 EP EP11160654.7A patent/EP2407470A3/fr not_active Withdrawn
- 2004-10-13 CA CA002540858A patent/CA2540858C/fr active Active
- 2004-10-13 ES ES04795169T patent/ES2398912T3/es active Active
- 2004-10-13 PL PL04795169T patent/PL1680137T3/pl unknown
- 2004-10-13 TW TW093131036A patent/TWI375679B/zh active
- 2004-10-13 KR KR1020067007146A patent/KR100853579B1/ko active IP Right Grant
- 2004-10-13 MX MXPA06003963A patent/MXPA06003963A/es active IP Right Grant
- 2004-10-13 CN CN201010524190.9A patent/CN102020697B/zh active Active
- 2004-10-13 RS RS20110578A patent/RS20110578A3/en unknown
- 2004-10-13 EA EA200600732A patent/EA011857B8/ru not_active IP Right Cessation
- 2004-10-13 AP AP2006003579A patent/AP2287A/xx active
- 2004-10-13 PT PT47951694T patent/PT1680137E/pt unknown
- 2004-10-13 OA OA1200600121A patent/OA13315A/en unknown
- 2004-10-13 RS YUP-2006/0259A patent/RS20060259A/sr unknown
- 2004-10-13 TW TW101112677A patent/TW201245229A/zh unknown
- 2004-10-13 BR BRPI0415373-1A patent/BRPI0415373A/pt not_active Application Discontinuation
- 2004-10-13 EP EP04795169A patent/EP1680137B1/fr active Active
- 2004-10-13 CN CN201310025494.4A patent/CN103145715B/zh active Active
- 2004-10-13 GE GEAP20049383A patent/GEP20084560B/en unknown
- 2004-10-13 RS RS20060259A patent/RS54573B1/en unknown
- 2004-10-13 NZ NZ546347A patent/NZ546347A/en unknown
- 2004-10-13 JP JP2006535671A patent/JP4584260B2/ja active Active
- 2004-10-13 AU AU2004281780A patent/AU2004281780B2/en active Active
- 2004-10-13 DK DK04795169.4T patent/DK1680137T3/da active
- 2004-10-13 WO PCT/US2004/033970 patent/WO2005037214A2/fr active Application Filing
- 2004-10-14 AR ARP040103730A patent/AR046422A1/es active IP Right Grant
- 2004-10-14 MY MYPI20044222A patent/MY144593A/en unknown
-
2006
- 2006-03-30 IL IL174704A patent/IL174704A/en active IP Right Grant
- 2006-03-31 IS IS8395A patent/IS2876B/is unknown
- 2006-04-11 AP AP2011005830A patent/AP2011005830A0/xx unknown
- 2006-05-08 MA MA29013A patent/MA28152A1/fr unknown
- 2006-05-09 NO NO20062089A patent/NO343231B1/no unknown
- 2006-05-12 EC EC2006006570A patent/ECSP066570A/es unknown
-
2007
- 2007-01-19 HK HK07100728.2A patent/HK1100164A1/xx unknown
-
2010
- 2010-07-08 JP JP2010155686A patent/JP5143870B2/ja active Active
-
2011
- 2011-02-16 AR ARP110100466A patent/AR080189A2/es not_active Application Discontinuation
- 2011-10-25 IL IL215933A patent/IL215933A0/en unknown
- 2011-10-25 IL IL215934A patent/IL215934A0/en unknown
-
2012
- 2012-06-01 EC ECSP12011944 patent/ECSP12011944A/es unknown
- 2012-09-25 JP JP2012210615A patent/JP2013006870A/ja active Pending
-
2013
- 2013-01-17 CY CY20131100048T patent/CY1113809T1/el unknown
- 2013-02-05 HR HRP20130098TT patent/HRP20130098T1/hr unknown
- 2013-08-29 HK HK13110111.8A patent/HK1182710A1/zh unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6608027B1 (en) * | 1999-04-06 | 2003-08-19 | Boehringer Ingelheim (Canada) Ltd | Macrocyclic peptides active against the hepatitis C virus |
WO2003053349A2 (fr) * | 2001-12-20 | 2003-07-03 | Bristol-Myers Squibb Company | Inhibiteurs de virus de l'hepatite c |
WO2003066103A1 (fr) * | 2002-02-07 | 2003-08-14 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compositions pharmaceutiques pour inhibiteurs de protease virale de l'hepatite c |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AP2287A (en) | Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication. | |
IL182712A0 (en) | (biphenyl) carboxylic acids and derivatives thereof | |
AU2003261434A8 (en) | Iminothiazolidinones as inhibitors of hcv replication | |
TWI306412B (en) | Homogeneous process for the hydrogenation of carboxylic acids and/or derivatives thereof | |
AU2001249670A1 (en) | Substituted thiazoles and the use thereof as inhibitors of plasminogen activatorinhibitor-1 | |
MXPA03009565A (es) | Derivado de acido carboxilico y una sal del mismo. | |
AU2003221786A1 (en) | Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors | |
IL172471A0 (en) | Gsk-3 inhibitors and uses thereof | |
AU2001234088A1 (en) | TNF-alpha inhibitors | |
ZA200400024B (en) | Bag and method of moving. | |
EP1816128A4 (fr) | Dérivé d acide carboxylique contenant un cycle thiazole et applications pharmaceutiques dudit dérivé | |
ZA200410054B (en) | Propionic acid derivatives and their use as hPPARsactivators. | |
AU2003301883A1 (en) | Modified luciferase nucleic acids and methods of use | |
PL374581A1 (en) | Diaminothiazoles and use thereof as cdk4 inhibitors | |
AU2002356276A1 (en) | Quinline derivates and their use as mek inhibitors | |
AU2003268795A1 (en) | Pallets and methods for manufacture and use thereof | |
AU2001232245A1 (en) | Tnf- alpha inhibitors | |
MXPA03008614A (es) | Metodos para usar acidos de lupulo para controlar organismos. | |
AU2003258564A1 (en) | Gas odorisation using carboxylic acids and alkynes | |
SI1680137T1 (sl) | Makrocikliäśna karboksilna kislina in acilsulfonamidna spojina kot inhibitor replikacije hcv | |
AU2003295615A8 (en) | Devices and methods for forming magnetic anastomoses between vessels | |
AU2003215146A8 (en) | Snares and methods of controlling cytokinesis | |
AU2003238948A1 (en) | Caspase-1 inhibitors and methods for their use | |
ZA200703258B (en) | (Biphenyl) carboxylic acids and derivatives thereof | |
HK1115579A1 (en) | (biphenyl) carboxylic acids and derivatives thereof () |